MARKET

CVM

CVM

CEL SCI
AMEX

Real-time Quotes | Nasdaq Last Sale

16.09
+1.43
+9.75%
Closed 17:55 02/19 EST
OPEN
14.80
PREV CLOSE
14.66
HIGH
16.30
LOW
14.63
VOLUME
1.37M
TURNOVER
--
52 WEEK HIGH
16.30
52 WEEK LOW
2.367
MARKET CAP
585.52M
P/E (TTM)
-18.2137
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CVM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CVM News

  • Cel-Sci: The Upside Is Still There
  • Seeking Alpha - Article.6d ago
  • CEL-SCI (CVM) Investor Presentation - Slideshow
  • Seeking Alpha - Article.02/11 18:19
  • Cel-Sci EPS misses by $0.01
  • seekingalpha.02/10 18:07
  • CEL-SCI Q1 EPS $(0.16) Down From $0.02 YoY
  • Benzinga.02/10 13:01

More

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.22%

Hot Stocks

Name
Price
%Change

About CVM

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.
More

Webull offers CEL-SCI Corporation (CVM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.